US Court Rules in Favor of Sanofi and Regeneron in Praluent Patent Case
A District Court for the US District of Delaware has ruled in favor of Sanofi and Regeneron in the patent case targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).
A District Court for the US District of Delaware has ruled in favor of Sanofi and Regeneron in the patent case targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), it was revealed in an Aug. 29, 2019 press statement.
The ruling was made due to a “lack of enablement” it was specified in the press release and has meant that sections of an earlier jury verdict have been overturned. As a result of this latest court ruling, Sanofi and Regeneron have invalidated all five patent claims made against them by Amgen.
“It has been our longstanding belief that all of Amgen’s asserted US PCSK9 patent claims are invalid, and we are pleased today’s decision reaffirms this,” said Karen Linehan, executive vice-president and general counsel, Sanofi, in the press release.
“Today’s decision by the US District Court for the District of Delaware validates our position that Amgen’s patents are overly broad and invalid,” added Joseph LaRosa, executive vice-president, general counsel and secretary, Regeneron. “Praluent was developed using Regeneron’s proprietary science and technology, and the judge has confirmed our position by issuing this ruling.”
Source: Sanofi
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
